Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero

Acta Pharmacologica Sinica

Volumn 25, Issue 6, 2004, Pages 789-793

  Chen, Xiao Guang ^a   Zhu, Huan Zhang ^a   Gong, Ju Li ^a   Li, Feng ^a   Xue, Jing Lun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Factor IX; Gene transfer techniques; In utero; Lentiviral vector

Indexed keywords

BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; DNA; HUMAN BLOOD CLOTTING FACTOR 9; LENTIVIRUS VECTOR; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; GENE EXPRESSION; GENE TRANSFER; GERM LINE; GESTATIONAL AGE; HEART; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRENATAL CARE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TIME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; ANIMALS, NEWBORN; DNA, COMPLEMENTARY; FACTOR IX; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; LIVER; MICE; MICE, INBRED ICR; PREGNANCY; RECOMBINANT PROTEINS; SPLEEN; TRANSGENES; UTERUS;

EID: 2942629386     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Walsh CE. Gene therapy progress and prospects: gene therapy for the hemophilias. Gene Ther 2003; 10: 999-1003.
2. Kay MA, High K. Gene therapy for hemophilia. Proc Natl Acad Sci USA 1999; 96: 9973-5.
3. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science 1999; 285: 2084-8.
4. Walsh CE. Perspective: fetal gene therapy. Gene Ther 1999; 6: 1200-1.
5. Senut MC, Gage FH. Prenatal gene therapy: can the technical hurdles be overcome? Mol Med Today 1999; 5: 152-6.
6. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F H, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
7. Park F, Ohashi K, Kay MA. Theraputic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-6.
8. Zahler MH, Irani A, Malhi H, Reutens AT, Albanese C, Bouzahzah B, et al. The application of a lentiviral vector for gene transfer in fetal human hepatocytes. J Gene Med 2000; 2: 186-93.
9. MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6: 349-58.
10. Zhu HZ, Chen XG, Li F, Gong JL, Xue JL. Expression of human clotting factor mediated by recombinant lentiviral vector in cultured cells and hemophilia B mice. Chin Sci Bull 2003; 48: 2196-200.
11. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-72.
12. Schneider H, Muhle C, Douar AM, Waddington S, Jiang QJ, Mark KD. Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4: 46-53.
13. Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, et al. Production of human clotting factor IX without toxicity in mice after vascular delivery of alentiviral vector. Nat Biotechnol 2002; 20: 53-7.
14. Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H. Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Ann Hematol 1998; 76: A1-6.